



ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



BRIEF COMMUNICATION

Neutrophil Extracellular Trap (NET) Markers in Psoriasis: Linking With Disease Severity and Comorbidities

J. Arroyo-Andrés^{a,*}, A. Gotor Rivera^a, B. Díaz-Benito^b, A. Moraga^b, I. Lizasoain Hernández^b, R. Rivera-Díaz^a

^a Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain

^b Department of Pharmacology and Toxicology, Complutense Medical School, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain

Received 1 July 2024; accepted 20 October 2024

KEYWORDS

Psoriasis;
Cardiovascular risk;
Psoriatic arthritis;
NETs;
Neutrophil extracellular traps;
Myeloperoxidase

Abstract Psoriatic patients have shown higher levels of neutrophil extracellular traps (NETs) vs healthy controls. Psoriasis is often associated with other comorbidities such as cardiovascular disease. An increase in indirect markers of NETs has been found in patients with increased cardiovascular events in patients without psoriasis. We conducted a prospective observational study with psoriatic patients. A total of 39 of patients were included. Myeloperoxidase, neutrophil elastase and double-stranded DNA were significantly higher in patients with severe-to-moderate vs mild psoriasis. Myeloperoxidase was also significantly higher in patients of moderate high vs low cardiovascular risk ($p = .01$) in patients with mild psoriasis. Patients with psoriatic arthritis show higher myeloperoxidase levels higher vs those without arthritis ($p = .048$). Myeloperoxidase was also significantly correlated ($p = .0375$) with the patients' BMI. The detection of NETs through indirect markers (myeloperoxidase, neutrophil elastase and double-stranded DNA) is associated with the severity of psoriasis. In addition, myeloperoxidase can be useful in psoriatic patients as biomarkers of comorbidities.

© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Psoriasis;
Riesgo cardiovascular;
Artritis psoriásica;

Marcadores indirectos de NETs (trampas extracelulares de neutrófilos) en pacientes con psoriasis: asociación con gravedad y comorbilidades

Resumen Los pacientes con psoriasis presentan niveles más elevados de trampas extracelulares de neutrófilos que los controles sanos. La psoriasis a menudo se asocia con otras comorbilidades como las enfermedades cardiovasculares. Se realizó un estudio prospectivo

* Corresponding author.

E-mail address: a.a.jorge@hotmail.com (J. Arroyo-Andrés).

<https://doi.org/10.1016/j.ad.2024.10.076>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

TNE;
Trampas
extracelulares de
neutrófilos;
Mieloperoxidasa

en pacientes con psoriasis. Se incluyeron 39 pacientes. La mieloperoxidasa, elastasa de neutrófilos y el ADN de doble cadena fueron significativamente más altas en los pacientes con psoriasis grave-moderada frente a leve. La mieloperoxidasa también fue significativamente mayor en pacientes con riesgo cardiovascular moderado-alto frente a bajo ($p=0,01$). Los pacientes con artritis psoriásica tienen niveles de mieloperoxidasa más altos en comparación con los que no tienen artritis ($p=0,048$). La mieloperoxidasa también se correlacionó significativamente ($p=0,0375$) con el Índice de Masa Corporal de los pacientes. La detección de las trampas extracelulares de neutrófilos a través de marcadores indirectos está relacionada con la gravedad de la psoriasis. Además, la mieloperoxidasa, podría ser útil como biomarcador de comorbilidades.

© 2025 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Psoriasis is a chronic inflammatory disease that affects almost 2% of the population.¹ In addition to skin involvement, patients with psoriasis often associate other diseases such as psoriatic arthritis (PsA), metabolic syndrome, or cardiovascular disease.

Although it was initially linked to an increased prevalence of other cardiovascular risk factors, it has been hypothesized that psoriasis may behave as an independent cardiovascular risk factor, especially in young patients with severe psoriasis.²

Identifying patients with psoriasis and high cardiovascular risk would allow prevention strategies to be implemented early. To this end, in recent years multiple biomarkers³ or imaging modalities have been studied,⁴ the latter techniques being difficult to generalize to all patients.

Several observations have convinced researchers that T cells (and specially Th17 cells) are crucial in the pathogenesis of psoriasis. Although neutrophils are present in psoriatic lesions, their possible involvement in the pathogenesis of the disease is unclear.⁵ The role of innate immunity in the pathogenesis of psoriasis is becoming increasingly important, and an integrated system of innate and adaptive immunity has been suggested.⁶

Neutrophils are important components of innate immunity and a primary defense vs microbial infections. Neutrophil extracellular traps (NETs) were described for the first time in 2004. NETosis is a form of programmed cell death like apoptosis or necrosis, in which neutrophils, after decondensing their chromatin, expel it into the extracellular medium forming 3D chromatin networks. The presence of NETosis can be detected either directly by immunohistochemical staining in circulating tissue/cells or indirectly by detection of biomarkers in blood by ELISA.⁷

Although the main function of NETs was initially thought to trap and kill pathogens, NET formation has been observed during chronic inflammatory disease, autoimmune diseases, or thrombosis.⁸ Higher levels of NETs have been shown in other skin diseases such as hidradenitis suppurativa,⁹ or pyoderma gangrenosum.¹⁰

On the other hand, diseases that present an intense inflammatory cascade and immunothrombosis phenomena, such as COVID-19, may present skin rashes that have shown

the presence of neutrophils, suggesting the presence of NETosis.¹¹ In fact, it has been hypothesized that NETosis plays a role in the shared pathophysiological links between psoriasis and COVID-19 comorbidities.¹²

Prospective studies have found higher dsDNA levels in patients with increased cardiovascular events at the 2-year follow-up.¹³

Elevated levels of NETs markers such as double-stranded DNA (dsDNA) have been independently associated with severe coronary atherosclerosis.¹⁴

In atherosclerosis, both the process of atherosclerotic lesion development and atherothrombosis has been related to NETs. In murine models of atherosclerosis, blocking the formation of NETs reduced the size of plaques and the occurrence of thrombosis, suggesting a significant role of NETs in pathogenesis.¹⁵

Indirect markers of NETs, both myeloperoxidase (MPO) and neutrophil elastase (NE), are elevated in patients with plaque psoriasis vs healthy controls.^{16,17} In addition, Hu et al.¹⁸ found that the number of NETotic cells in peripheral blood was higher in patients with psoriasis vs healthy controls. Furthermore, the cells increased according to the severity measured with psoriasis area and severity index (PASI). However, indirect markers of NETs were not studied in this case.

No studies on the association of NETs with the comorbidities frequently associated with psoriatic patients have been reported.

Materials and methods

We conducted a prospective observational study with psoriatic patients without systemic treatment attending our hospital dermatology department. This study was approved by our hospital Medical Ethics Committee, and all patients gave their informed consent prior to being included in the study.

We collected the patients' demographic characteristics, and quantified the severity of psoriasis using the PASI (Psoriasis Area severity Index), considering mild psoriasis PASI <7 and moderate-to-severe psoriasis PASI ≥ 7 ,¹⁹ and the Physicians' Global Assessment (PGA) scale (0–4), considering mild psoriasis PGA 1–2 and moderate-to-severe psoriasis, PGA 3–4. The cardiovascular risk of patients was quantified using the SCORE2 (European Society of Cardiology – ESC), and

patients were categorized as mild-to-moderate and high-to very high cardiovascular risk according to this scale.²⁰

After obtaining platelet-poor plasma from venous blood samples, enzyme-linked immunosorbent assays were performed to measure the levels of three different NETs biomarkers: dsDNA, MPO and NE.

Means and standard deviations were used for normally distributed continuous variables. Medians with interquartile ranges were used for non-normally distributed continuous variables. Inferences on quantitative variables were made using the Student *t* test or the Mann-Whitney *U* test, according to normality. *p*-Values <0.05 were considered statistically significant.

Results

A total of 39 patients were included. Clinical characteristics are shown in Table 1.

Indirect markers of NETs were not related to the severity of psoriasis according to PASI scale (*p* = .61). However, if the psoriasis severity was quantified with the PGA scale, MPO, NE and dsDNA were statistically significantly higher in patients with severe-to-moderate (PGA 3-4) vs mild psoriasis (PGA 1-2) (Fig. 1). Indirect markers were not related to body surface area (BSA) either.

Patients with moderate high cardiovascular risk (CVR) have significantly higher MPO (*p* = .0076) vs low, as well as higher neutrophil elastase yet not statistically significant (*p* = .0548).

MPO was also significantly higher in patients with moderate high vs low CVR (*p* = .01) in patients with mild psoriasis (PGA 1-2). However, no differences were found in patients with PGA 3-4.

Patients with psoriasis and associated psoriatic arthritis have MPO levels higher (71.67) vs those without arthritis (43.98) (*p* = .048). The characteristics of both groups with and without associated arthritis were compared, without finding any significant differences in any variable (severity, cardiovascular risk, ...).

MPO was also significantly correlated (*p* = .0375) with the patients' BMI. The remaining comorbidities and CVR factors, such as smoking, diabetes mellitus, dyslipidemia were not related to any of the indirect markers.

Discussion

Based on our results, the detection of NETs through indirect markers (MPO, NE, dsDNA) may be linked to severity on the PGA scale, not the PASI scale. Former studies had not found any associations of indirect markers of NETs with severity.^{16,21}

In our study we found that several patients with severe localized variants of psoriasis and low PASI score had similar levels of NETs in blood as patients with very extensive forms and high PASI score.

We consider the detection of NETs as an indirect marker of the inflammatory intensity of skin lesions. However, NET levels might not specifically be related to the affected body surface area.

The difference found between both severity scales reinforces the possibility of underestimating the severity of the

Table 1 Clinical characteristics of the patients.

Baseline characteristics	
<i>N</i>	39
<i>Age (years), m (SD)</i>	48.33 (13.44)
<i>Sex</i>	
Male	23 (59%)
Female	16 (41%)
<i>Pso duration (years), m (SD)</i>	16.26 (13.64)
<i>Time from last flare (months), m (SD)</i>	8.10 (19.01)
<i>BMI (kg/m²), m (SD)</i>	29.95 (6.38)
<i>BMI</i>	
Normal	9 (24%)
Overweight	11 (27%)
Obesity	19 (49%)
<i>Type of psoriasis, n (%)</i>	
Plaque	32 (82%)
Guttata	1 (2%)
Generalized pustular psoriasis	3 (8%)
Palmoplantar pustular psoriasis	3 (8%)
<i>Psoriatic arthritis, n (%)</i>	
No	27 (69%)
Yes	12 (31%)
<i>Diabetes mellitus, n (%)</i>	
No	32 (81%)
Yes	7 (19%)
<i>Current smoker, n (%)</i>	
No	20 (52%)
Yes	19 (48%)
<i>HTA, n (%)</i>	
No	25 (64%)
Yes	14 (36%)
<i>Dyslipidemia, n (%)</i>	
No	22 (57%)
Yes	17 (43%)
<i>Cardiovascular risk SCORE2 (ESC), n (%)</i>	
Low	17 (44%)
Moderate/high	22 (56%)
<i>PASI basal, m (SD)</i>	13.74 (9.20)
<i>Severity psoriasis PGA, n (%)</i>	
Mild (PGA 1-2)	25 (64%)
Moderate-Severe (PGA 3-4)	14 (36%)

disease with PASI scale in localized psoriasis variants or those whose affected body surface area is minimal, which corresponds to low PASI score. However, these patients might exhibit moderate or intense inflammation. In these cases, NETs can behave as a biomarker that may play an interesting role in therapeutic decision-making.

In addition, in our patients we have also observed that the presence of psoriatic arthritis (PsA) was associated with higher levels of MPO. These data are consistent with former studies that had also found higher levels of other indirect markers of NETs in patients with PsA (such as DNA-MPO complexes).²² Since our sample is limited, we have not been




Figure 1 Indirect markers of neutrophil extracellular traps (NETs) in psoriasis. (a) Indirect NET markers by psoriasis severity (PGA): This panel shows indirect markers of NETs – myeloperoxidase (MPO, yellow), neutrophilic elastase (NE, green), and double-stranded DNA (dsDNA, blue) – in patients with plaque psoriasis. Data are stratified by disease severity using the Physician's Global Assessment (PGA): mild psoriasis (PGA 1-2) vs moderate-to-severe psoriasis (PGA 3-4). Means and p-values are displayed, with 'n' indicating the number of patients in each group. (B) Myeloperoxidase (MPO) levels by psoriasis severity and cardiovascular risk (SCORE2): This box plot illustrates MPO levels in plaque psoriasis patients, categorized by both psoriasis severity (PGA) and cardiovascular risk (CVR) as assessed by SCORE2. Groups are defined as: mild psoriasis with low CVR (blue), mild psoriasis with moderate-to-high CVR (orange), moderate-to-severe psoriasis with moderate-to-high CVR (yellow), and moderate-to-severe psoriasis with low CVR (grey). (C) Indirect NET markers by psoriatic arthritis (PsA) association: This panel presents means and p-values for MPO, NE, and dsDNA in plaque psoriasis patients. Data are differentiated based on the presence (green) or absence (red) of psoriatic arthritis (PsA).

able to establish MPO cut-off point indicating the presence of arthritis.

Regarding CVR, MPO could behave as a biomarker of CVR, at least, in patients with mild psoriasis (PGA 1-2). The role of NETs as a biomarker of CVR in other conditions such as gout has been studied, without finding differences.²³ However, its possible association with psoriatic patients had not been studied, or at least published to this date.

Based on our study, we consider that indirect markers of NETs, especially MPO, may be useful in psoriatic patients as biomarkers of comorbidities such us PsA and CVR, at least in patients with mild psoriasis.

Furthermore, these indirect markers may help clinicians in the therapeutic decision-making especially by identifying patients with other comorbidities or patients with intense inflammation despite presenting a minimal body surface area affected.

Our study has several limitations, including its small sample size. To confirm these preliminary findings, larger studies are needed that can account for cardiovascular risk factors. Additionally, current cardiovascular risk (CVR) scales are not specifically designed for psoriasis patients, highlighting a need for future research to establish reference values and cut-off points. Prospective studies with more patients and longer follow-up periods are also essential to investigate how systemic psoriasis treatments might alter NET levels.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Boehncke WH, Schön MP. Psoriasis. *Lancet*. 2015;386:983–94.
- Gelfand JM, Neumann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA*. 2006;296:1735–41, <http://dx.doi.org/10.1001/jama.296.14.1735> [PMID: 17032986].
- Colaco K, Lee KA, Akhtari S, Winer R, Welsh P, Sattar N, et al. Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. *Ann Rheum Dis*. 2021;80:1429–35.
- Gonzalez-Cantero A, Reddy AS, Dey AK, Gonzalez-Cantero J, Munger E, Rodante J, et al. Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. *Eur J Prev Cardiol*. 2022;29:591–8.
- Di Domizio J, Gilliet M. Psoriasis caught in the NET. *J Invest Dermatol*. 2019;139:1426–9.
- van de Kerkhof PC. From empirical to pathogenesis-based treatments for psoriasis. *J Invest Dermatol*. 2022;142:1778–85, <http://dx.doi.org/10.1016/j.jid.2022.01.014> [Epub 3 March 2022; PMID: 35249726].
- Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. *Science*. 2004;303:1532–5, <http://dx.doi.org/10.1126/science.1092385> [PMID: 15001782].
- Zawrotniak M, Rapala-Kozik M. Neutrophil extracellular traps (NETs) – formation and implications. *Acta Biochim Pol*. 2013;60:277–84.
- Oliveira CB, Byrd AS, Okoye GA, Kaplan MJ, Carmona-Rivera C. Neutralizing anti-DNase 1 and -DNase 1L3 antibodies impair neutrophil extracellular traps degradation in hidradenitis suppurativa. *J Invest Dermatol*. 2023;143:57–66.

10. Li S, Ying S, Wang Y, Lv Y, Qiao J, Fang H. Neutrophil extracellular traps and neutrophilic dermatosis: an update review. *Cell Death Discov.* 2024;10:18.
11. Herrero-Moyano M, Capusan TM, Andreu-Barasoain M, Alcántara-González J, Ruano-Del Salado M, Sánchez-Largo Uceda ME, et al. A clinicopathological study of eight patients with COVID-19 pneumonia and a late-onset exanthema. *J Eur Acad Dermatol Venereol.* 2020;34:e460–4.
12. Llamas-Velasco M, Ovejero-Merino E, Salgado-Boquete L. Obesidad: factor de riesgo para psoriasis y COVID-19 [Obesity – a risk factor for psoriasis and COVID-19]. *Actas Dermosifiliogr.* 2021;112:489–94.
13. Langseth MS, Opstad TB, Bratseth V, Solheim S, Arnesen H, Pettersen ÅÅ, et al. Markers of neutrophil extracellular traps are associated with adverse clinical outcome in stable coronary artery disease. *Eur J Prev Cardiol.* 2018;25:762–9.
14. Borisoff JI, Joosen IA, Versteylen MO, Brill A, Fuchs TA, Savchenko AS, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. *Arterioscler Thromb Vasc Biol.* 2013;33:2032–40.
15. Mostafa MN, Osama M. The implications of neutrophil extracellular traps in the pathophysiology of atherosclerosis and atherothrombosis. *Exp Biol Med.* 2020;245:1376–84.
16. Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. *Arterioscler Thromb Vasc Biol.* 2015;35:2667–76.
17. Cao LY, Soler DC, Debanne SM, Grozdev I, Rodriguez ME, Feig RL, et al. Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions. *Am J Transl Res.* 2013;6:16–27.
18. Hu SC, Yu HS, Yen FL, Lin CL, Chen GS, Lan CC. Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes. *Sci Rep.* 2016;6:31119.
19. Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Moderate psoriasis: a proposed definition. *Actas Dermosifiliogr.* 2017;108:911–7.
20. SCORE2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J.* 2021;42:2439–54.
21. Cao LY, Soler DC, Debanne SM, Grozdev I, Rodriguez ME, Feig RL, et al. Psoriasis and cardiovascular risk factors: increased serum myeloperoxidase and corresponding immunocellular overexpression by Cd11b(+) CD68(+) macrophages in skin lesions. *Am J Transl Res.* 2013;6:16–27.
22. Li B, Li G, Yang X, Song Z, Wang Y, Zhang Z. NETosis in psoriatic arthritis: serum MPO–DNA complex level correlates with its disease activity. *Front Immunol.* 2022;13:911347.
23. Vedder D, Gerritsen M, Duvvuri B, van Vollenhoven RF, Nur-mohamed MT, Lood C. Neutrophil activation identifies patients with active polyarticular gout. *Arthritis Res Ther.* 2020;22:148.